Michael Topf MD, MSCI

Head and Neck Surgical Oncologist @VanderbiltENT | pelotopf on @onepeloton | Views are my own

[Michael Topf MD, MSCI @TopfHNS]

@PaulJiL @ASCO Curious to hear about how unfavorable was defined and what biomarker was used.

[Michael Topf MD, MSCI @TopfHNS]

@StergiosDoumas @qvh @VanderbiltENT A true privilege to connect with @StergiosDoumas and NHS Queen Victoria Hospital and discuss approaches to head and neck cancer margins and WPOI. @VanderbiltENT #oralcancer

[Michael Topf MD, MSCI @TopfHNS]

Appreciate all of your insight! Look forward to future studies.

[Dr. Scott Fortune @DrScottFortune]

Thanks to @TopfHNS @haynes_ear @VanderbiltENT @AAOHNS @OTOjournals #topviewedarticles #top10percent #wileyonline
Proud to be a standard bearer!

[Michael Topf MD, MSCI @TopfHNS]

@HeadNeckMD @NatureComms @Naveris_inc @DanaFarberNews @jdschoenfeld1 Congrats! The disease needs a biomarker. This trial makes perfect sense.

[Michael Topf MD, MSCI @TopfHNS]

@DavidSherMD Nice thread. Agree 100% the disease needs a biomarker.

One additional point is that 70 Gy and cis demonstrated 98% 2 yr PFS on HN005.

Is there a PFS decrease that we are willing to accept as a field given the functional morbidity of 70 Gy and salvage options?

[VUMC Otolaryngology–Head and Neck Surgery @VanderbiltENT]

Dr. Sidharth Puram, pictured with some of our Head and Neck faculty, gave a great presentation at Grand Rounds this morning.

[Michael Topf MD, MSCI @TopfHNS]

@DrSpratticus @CanesDavid I think true meaningful surgery is far in the future for AI / robotics. The professional fees for many operations aren’t actually all that much when weighed against the medical malpractice risk. Semi-autonomous where risk / responsibility falls on the surgeon will be first.

[Andreja Radevic @RadevicAndreja]

Had some great discussions when @JLAusterlitz presented our new augmented reality work at @virtualmedconf !

Thank you to @TopfHNS for your support and guidance and @virtualmedconf for the opportunity to present.

@VanderbiltENT

[VUMC Otolaryngology–Head and Neck Surgery @VanderbiltENT]

Join promising otolaryngology residents, fellows, and faculty for lectures, workshops, and panels focusing on the keys to research success. Participants will leave motivated and equipped with the tools to achieve success in translational research. https://t.co/ZFER4ePY9o

[Michael Topf MD, MSCI @TopfHNS]

@SprakerMDPhD Proud of my society @AAOHNS for paving the way. Thank you Dr. Shah!

[Michael Topf MD, MSCI @TopfHNS]

@free_radical28 Are their concerns about the quality of the plans on trial?

[David Sher @DavidSherMD]

Come for the critically important data on protons for oropharyngeal cancer, stay for the beautifully written paper.

TORPEdO is out, and it is fascinating and instructive.

I will warn you upfront that this is a long thread, but there is a lot here to discuss!

https://t.co/zvvenb2Zpl

[Michael Topf MD, MSCI @TopfHNS]

@jryckman3 @SprakerMDPhD @TheLancet This is a very well written thread with excellent critique 👊🏻

[VUMC Otolaryngology–Head and Neck Surgery @VanderbiltENT]

Congratulations to our new incoming residents! #MatchDay #VUMC #ENT

[Michael Topf MD, MSCI @TopfHNS]

@SprakerMDPhD @HardenedBeam THIS

Rad onc that treats only or mostly H&N is biggest differentiator.

And it’s amazing how much difference there is in toxicity between providers and centers.

[Michael Topf MD, MSCI @TopfHNS]

@EvanThomas84 To follow up - I am worried about RT for VC vs RT for reg SCC. Two different disease processes.

[Michael Topf MD, MSCI @TopfHNS]

@EvanThomas84 There are 33 patients in the RT arm. Come on now. Let’s be serious about the analysis of this paper.

[Michael Topf MD, MSCI @TopfHNS]

@EvanThomas84 Did you read this PLOS ONE paper - or just abstract?

retrospective, not powered to detect a difference, and surgery curve quite a bit higher at 2y. Just because it’s PMID doesn’t mean it’s well done.

This paper actually makes me want to operate on VC more than I did previously.